nach oben

Drug Safety

Erschienen in:

01.03.2012 | Systematic Reviews

Oral Contraceptives and Venous Thromboembolism

A Systematic Review and Meta-Analysis

verfasst von: Dr Lamberto Manzoli, Corrado De Vito, Carolina Marzuillo, Antonio Boccia, Paolo Villari

Erschienen in: Drug Safety | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Background: An association between oral contraceptive (OC) use and venous thromboembolism (VTE) has long been recognized. However, no summary estimates of the increase in VTE risk associated with OC use have been available since 1995, and no meta-analyses have evaluated the VTE risk of new preparations containing drospirenone.

Objective: The aim of the study was to carry out a meta-analysis to summarize existing evidence on the association between venous VTE and OC use, and to investigate how such an association may vary according to the type of OC, OC user characteristics, study characteristics and biases.

Methods: Relevant cohort or case-control studies were searched in MEDLINE and other electronic databases up to May 2010, with no language restriction. Data were combined using a generic inverse-variance approach. Meta-regression in addition to stratification was used to explore potential predictors of the summary estimate of risk.

Results: Sixteen cohort and 39 case-control studies were included in at least one comparison. Overall, the odds ratio (OR) of OC users versus non-users was 3.41 (95% CI 2.98, 3.92). This estimate was based upon nine cohort studies evaluating approximately 12 000 000 person-years, and 23 case-control studies including approximately 45 000 women. VTE risk for OC users was significantly lower in studies evaluating ‘all VTE cases’ than in those evaluating ‘idiopathic VTE only’ (OR 3.09 and 4.94, respectively). Among the carriers of genetic mutations G20210A and Factor V Leiden (FVL), OC users showed a significantly increased VTE risk compared with non-users (OR 1.63; 95% CI 1.01, 2.65, and OR 1.80; 95% CI 1.20, 2.71, respectively). When the newest OCs containing drospirenone were compared with non-drospirenone-containing OCs (except those containing levonorgestrel only), VTE risk did not significantly increase (OR 1.13; 95% CI 0.94, 1.35).

Conclusions: This meta-analysis confirms that OC use significantly increases VTE risk. The strength of this association, however, varies according to the generation of OC, type of outcome and presence of a genetic mutation, with ORs ranging from 3 to 5.

Mosher WD, Jones J. Use of contraception in the United States: 1982–2008. Vital Health Stat 2010 Aug; 23 (29): 1–44

World Health Organization. Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 1998; 877: i–vii, 1–89

Barritt DW, Jordan WM. Clinical features of pulmonary embolism. Lancet 1961 Apr 8; I (7180): 729–32

Poulter NR, Chang CL, Farley TMM, et al. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995 Dec 16; 346 (8990): 1575–82

Spitzer WO, Lewis MA, Heinenmann LA, et al. Thirdgeneration oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996 Jan 13; 312 (7023): 83–8

Bloemenkamp KW, Rosendaal FR, Bu¨ ller HR, et al. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 1999 Jan 11; 159 (1): 65–70PubMed

Farmer RDT, Lawrenson RA, Todd J-C, et al. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol 2000 Jun; 49 (6): 580–90PubMedCrossRef

Lidegaard , Lokkegaard E, Svendsen AL, et al. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009 Aug 13; 339: b2890

van Hylckama V, Helmerhost FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009 Aug 13; 339: b2921 202 Manzoli et al.

10.

Heinemann LAJ, Lewis MA, Assmann A, et al. Casecontrol studies on venous thromboembolism: bias due to design? A methodological study on venous thromboembolism and steroid hormone use. Contraception 2002 Mar; 65 (3): 207–14PubMedCrossRef

11.

Mohllajee AP, Curtisa KM, Martins SL, et al. Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? A systematic review. Contraception 2006 Feb; 73 (2): 166–78PubMedCrossRef

12.

Vandenbroucke JP, Rosing J, BloemenkampKW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001 May 17; 344 (20): 1527–35CrossRef

13.

Wu O, Robertson L, Twaddle S, et al. Screening for thrombophilia in high-risk situations: systematic review and costeffectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 2006 Apr; 10 (11): 1–110PubMed

14.

Koster T, Small RA, Rosendaal FR, et al. Oral contraceptives and venous thromboembolism: a quantitative discussion of uncertainties. J InternMed 1995 Jul; 238 (1): 31–7CrossRef

15.

Pharmacy Times. Top 200 prescription drugs of 2009 [online]. Available from URL: http://www.pharmacytimes.com/issue/pharmacy/2010/May2010/RxFocusTopDrugs-0510 [Accessed 2011 Feb 9]

16.

Deeks JJ, Higgins JPT, Altman DG. Analysing and presenting results. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions 4.2.6. Section 8. The Cochrane Collaboration 2006 [online]. Available from URL: http://www.cochrane.org/sites/default/files/uploads/Handbook4.2.6Sep2006.pdf [Accessed 2011 Dec 29]

17.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–88PubMedCrossRef

18.

Orsini N. P2CI: Statamodule to calculate confidence limits of a regression coefficient from the p-value. Boston College Department of Economics: Statistical Software Components 2005. S449101 [online]. Available from URL: http://ideas.repec.org/c/boc/bocode/s449101.html [Accessed 2010 May 5]

19.

Sterne JAC, Egger M, Davey Smith G. Investigating and dealing with publication and other biases in meta-analysis. BMJ 2001 Jul 14; 323 (7304): 101–5

20.

Egger M, Schneider M, Davey Smith G. Spurious precision? Meta-analysis of observational studies. BMJ 1998 Jan 10; 316 (7125): 140–4PubMedCrossRef

21.

Egger M, Davey Smith G, Schneider M, et al. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997 Sep 13; 315 (7109): 629–34PubMedCrossRef

22.

Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994 Nov 26; 344 (8935): 1453–7

23.

Khader YS, Rice J, John L, et al. Oral contraceptives use and the risk of myocardial infarction: a meta-analysis. Contraception 2003 Jul; 68 (1): 11–7PubMedCrossRef

24.

Manzoli L, Villari P, Pirone GM, et al. Marital status and mortality in the elderly: a systematic review and metaanalysis. Soc Sci Med 2007 Jan; 64 (1): 77–94PubMedCrossRef

25.

Gohil R, Peck G, Sharma P. The genetics of venous thromboembolism. Thromb Haemost 2009 Aug; 102 (2): 360–70PubMed

26.

Lewis MA, Heinemann LAJ, MacRae KD, et al. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women [published erratum appears in Contraception 1996 Aug; 54 (2): [21]. Contraception 1996 Jul; 54 (1): 5–13PubMedCrossRef

27.

Lidegaard, EdstromB, Kreiner S. Oral contraceptives and venous thromboembolism: a case-control study. Contraception 1998 May; 57 (5): 291–301

28.

Lewis MA. The Transnational Study on Oral Contraceptives and the Health of Young Women: methods, results, new analyses and the healthy user effect. Hum Reprod Update 1999 Nov-Dec; 5 (6): 707–20

29.

Spitzer WO, Faith JM, MacRae KD. Myocardial infarction and third generation oral contraceptives: aggregation of recent studies. Hum Reprod 2002 Sep; 17 (9): 2307–14PubMedCrossRef

30.

Thompson SG, Sharp SJ. Explaining heterogeneity in metaanalysis: a comparison of methods. Stat Med 1999 Oct 30; 18 (20): 2693–708PubMedCrossRef

31.

Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003 Sep 6; 327 (7414): 557–60PubMedCrossRef

32.

Dinger JC, Heinemann LAJ, Khul-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007 May; 75 (5): 344–54PubMedCrossRef

33.

Royal College of Practitioners. Oral contraception, venous thrombosis, and varicose veins. J R Coll Gen Pract 1978 Jul; 28 (192): 393–9

34.

Porter JB, Hunter JR, Danielson DA, et al. Oral contraceptives and nonfatal vascular disease: recent experience. Obstet Gynecol 1982 Mar; 59 (3): 299–302PubMed

35.

Porter JB, Hunter JR, Jick H, et al. Oral contraceptives and nonfatal cardiovascular disease. Obstet Gynecol 1985 Jul; 66 (1): 1–4PubMed

36.

Vessey M, Mant D, Smith A, et al. Oral contraceptives and venous thromboembolism: findings in a large prospective study [letter]. BMJ (Clin Res Ed) 1986 Feb 22; 292 (6519): 526

37.

Gerstman BB, Piper JM, Tomita DK, et al. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991 Jan; 133 (1): 32–7PubMed

38.

Farmer RDT, Preston TD. The risk of venous thromboembolism associated with low oestrogen oral contraceptives. J Obstet Gynaecol 1995; 15: 195–200CrossRef

39.

Farmer R. Safety of modern oral contraceptives [letter]. Lancet 1996 Jan 27; 347 (8996): 259

40.

Lewis MA, MacRae KD, Ku¨ hl-Habichl D, et al. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 1999 Jun; 14 (6): 1493–9

41.

Burnhill MS. The use of a large-scale surveillance system in planned parenthood federation of America clinics to monitor cardiovascular events in users of combination oral contraceptives. Int J Fertil Womens Med 1999 Jan-Feb; 44 (1): 19–30

42.

Herings RMC, Urquhart J, Leufkens HGM. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999 Jul 10; 354 (9173): 127–8PubMedCrossRef

43.

Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999 Nov 6; 354 (9190): 1610–1

44.

Santamaria A, Mateo J, Oliver A, et al. Risk of thrombosis associated with oral contraceptives in women from 97 families with inherited thrombophilia: high risk of thrombosis in carriers of the G2021A mutation of the prothrombin gene. Haematologica 2001 Sep; 86 (9): 965–71PubMed

45.

Hedenmalm K, Samuelsson E, Spigset O. Pulmonary embolism associated with combined oral contraceptives: reporting incidences and potential isk factors for a fatal outcome. Acta Obstet Gynecol Scand 2004 Jun; 83 (6): 576–85PubMed

46.

Seeger JD, Loughlin J, Eng PM, et al. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol 2007 Sep; 110 (3): 587–93PubMedCrossRef

47.

Royal College of Practitioners. Oral contraception and thrombo-embolic disease. J R Coll Gen Pract 1967 May; 13 (3): 267–79

48.

Sartwell PE, Masi AT, Arthes FG, et al. Thromboembolism and oral contraceptives: an epidemiologic case-control study. Am J Epidemiol 1969 Nov; 90 (5): 365–80PubMed

49.

Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease: a further report. BMJ 1969 Jun 14; 2 (5658): 651–7PubMedCrossRef

50.

Boston Collaborative Drug Surveillance Programme. Oral contraceptives and venous thromboembolic disease, surgically confirmed gall-bladder disease, and breast tumours. Lancet 1973 Jun 23; 1 (7817): 1399–404

51.

Greenblatt DJ. A retrospective case-control study of diseases associated with oral contraceptive use. Am Heart J 1975 May; 89 (5): 677–8PubMedCrossRef

52.

Petitti DB, Wingerd J, Pellegrin F, et al. Oral contraceptives, smoking, and other factors in relation to risk of venous thromboembolic disease. Am J Epidemiol 1978 Dec; 108 (6): 480–5PubMed

53.

Maguire MG, Tonascia J, Sartwell PE, et al. Increased risk of thrombosis due to oral contraceptives: a further report. Am J Epidemiol 1979 Aug; 110 (2): 188–95PubMed

54.

Helmrich SP, Rosenberg L, Kaufman DW, et al. Venous thromboembolism in relation to oral contraceptive use. Obstet Gynecol 1987 Jan; 69 (1): 91–5PubMed

55.

World Health Organization Collaborative Study. Cardiovascular disease and use of oral contraceptives. Bull World Health Organ 1989; 67: 417–23

56.

Thorogood M, Mann J, Murphy M, et al. Risk factors for fatal venous thromboembolism in young women: a casecontrol study. Int J Epidemiol 1992 Feb; 21 (1): 48–52PubMedCrossRef

57.

Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, et al. Enhancement by factor V Leiden mutation of risk of deepvein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995 Dec 16; 346 (8990): 1593–6PubMedCrossRef

58.

Farley TMM, Meirik O, Chang CL, et al. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995 Dec 16; 346 (8990): 1582–8

59.

Lewis MA, Heinemann LAJ, MacRae KD, et al. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contraception 1996 Jul; 54 (1): 5–13PubMedCrossRef

60.

Suissa S, Blais L, Spitzer WO, et al. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997 Sep; 56 (3): 141–6PubMedCrossRef

61.

Andersen BS, Olsen J, Nielsen GL, et al. Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism. ThrombHaemost 1998 Jan; 79 (1): 28–31

62.

Bennet L, Odeberg H. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism. J Intern Med 1998 Jul; 244 (1): 27–32PubMedCrossRef

63.

Farmer RDT, Todd J-C, Lewis MA, et al. The risks of venous thromboembolic disease among German women using oral contraceptives: a database study. Contraception 1998 Feb; 57 (2): 67–70PubMedCrossRef

64.

Lidegaard . Thrombotic diseases in young women and the influence of oral contraceptives. Am J Obstet Gynecol 1998 Sep; 179 (3 Pt 2): S62–7

65.

Martinelli I, Taioli E, Bucciarelli P, et al. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999 Mar; 19 (3): 700–3PubMedCrossRef

66.

Todd J-C, Lawrenson R, Farmer RDT, et al. Venous thromboembolic disease and combined oral contraceptives: a reanalysis of the MediPlus database. Hum Reprod 1999 Jun; 14 (6): 1500–5PubMedCrossRef

67.

Aznar J, Vaya′ A, Estelle′ sA, et al. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives. Haematologica 2000 Dec; 85 (12): 1271–6PubMed

68.

Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, et al. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000 Jan 10; 160 (1): 49–52PubMedCrossRef

69.

Jick H, Kaye JA, Vasilakis-Scaramozza C, et al. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohortand case-control analysis. BMJ 2000 Nov 11; 321 (7270): 1190–5PubMedCrossRef

70.

Parkin L, Skegg DCG, Wilson M, et al. Oral contraceptives and fatal pulmonary embolism. Lancet 2000 Jun 17; 355 (9221): 2133–4PubMedCrossRef

71.

Spannagl M, Heinemann LAJ, Schramm W. Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism? Eur J Contracept Reprod Health Care 2000 Jun; 5 (2): 105–12PubMedCrossRef

72.

Suissa S, Spitzer WO, Rainville B, et al. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum Reprod 2000 Apr; 15 (4): 817–21PubMedCrossRef

73.

Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism: pooled analysis of 8 case-control studies including 2310 cases and 3240 controls [published erratum appears in Thromb Haemost 2001 Dec; 86 (6): 1598]. Thromb Haemost 2001 Sep; 86 (3): 809–16PubMed

74.

Legnani C, Palareti G, Guazzaloca G, et al. Venous thromboembolism in young women. Eur Heart J 2002 Jun; 23 (12): 984–90PubMedCrossRef

75.

Sidney S, Petitti DB, Soff GA, et al. Venous thromboembolic disease in users of low-estrogen combined estrogenprogestin oral contraceptives. Contraception 2004 Jul; 70 (1): 3–10PubMedCrossRef

76.

Jick SS, Kaye JA, Russmann S, et al. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Contraception 2006 Jun; 73 (6): 566–70PubMedCrossRef

77.

Pomp ER, Rosendaal FR, Doggen CJM. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol 2008 Feb; 83 (2): 97–102PubMedCrossRef

78.

Hennessy S, Berlin JA, Kinman JL, et al. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a metaanalysis and formal sensitivity analysis. Contraception 2001 Aug; 64 (2): 125–33PubMedCrossRef

79.

Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: metaanalysis. BMJ 2001 Jul 21; 323 (7305): 131–4PubMedCrossRef

80.

Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011; 340: d2151CrossRef

81.

Parkin L, Sharples K, Hernandez RK, et al. Risk of thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011; 340: d2139CrossRef

82.

Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA 2000 Jul 5; 284 (1): 72–8PubMedCrossRef

83.

Chan WS, Ray J, Wai EK, et al. Risk of stroke in women exposed to low-dose oral contraceptives: a critical evaluation of the evidence. Arch Intern Med 2004Apr 12; 164 (7): 741–7

84.

Baillargeon JP, McClish DK, Essah PA, et al. Association between the current use of low-dose oral contraceptivesand cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 2005 Jul; 90 (7): 3863–70PubMedCrossRef

85.

Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med 2011; 8 (5): e1001026

86.

Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007 Apr; 5 (4): 692–9PubMedCrossRef

87.

Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995 Feb 18; 310 (6977): 452–4PubMedCrossRef

88.

Anderson FA, Wheeler HB, Goldberg RJ, et al. A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med 1991 May; 151 (5): 933–8CrossRef

89.

Samuelsson E, Hedenmalm K, Persson I. Mortality from venous thromboembolism in young Swedish women and its relation to pregnancy and use of oral contraceptives: an approach to specifying rates. Eur J Epidemiol 2005; 20 (6): 509–16PubMedCrossRef

90.

Hoyert DL. Maternal mortality and related concepts. Vital Health Stat 2007 Feb 3; (33): 1–13

91.

World Health Organization. Medical eligibility criteria for contraceptive use. 3 rd ed. Geneva: World Health Organization, 2004

Titel: Oral Contraceptives and Venous Thromboembolism
A Systematic Review and Meta-Analysis
verfasst von: Dr Lamberto Manzoli
Corrado De Vito
Carolina Marzuillo
Antonio Boccia
Paolo Villari
Publikationsdatum: 01.03.2012
Verlag: Springer International Publishing
Erschienen in: Drug Safety / Ausgabe 3/2012
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI: https://doi.org/10.2165/11598050-000000000-00000

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

How are the Costs of Drug-Related Morbidity Measured?

Expectations for Feedback in Adverse Drug Reporting by Healthcare Professionals in the Netherlands

Targeting Outpatient Drug Safety

Paradoxical and Bidirectional Drug Effects

The Safety of an Adenosine A1-Receptor Antagonist, Rolofylline, in Patients with Acute Heart Failure and Renal Impairment